B2RLaw advises Neuca S.A. and Humaneva, Inc in a $50 million share acquisition by Viking Global Investors

B2RLaw, in cooperation with Pillsbury Winthrop Shaw Pittman LLP, advised Neuca S.A. and Humaneva, Inc. on the acquisition of a minority stake in Humaneva Inc. by Viking Global Investors for $50 million.

The transaction will contribute to the implementation of the long-term strategy in the area of clinical research and is a key step in strengthening the group’s position in the international biotechnology arena.

Humaneva, Inc., the parent company of Pratia, Kapadi, and Hyggio  – leaders in providing integrated clinical trial solutions – aims to accelerate the evolution of its business model. As a prominent player in the European market, Humaneva is now setting its sights on further expanding into the American and APAC regions, both recognized as hubs for advanced clinical trial activities. With over 90 dedicated and integrated Clinical Trial Centers (in six European countries), Humaneva plans to strengthen its proprietary technology offerings, focusing on eSource solutions, data integration, and analytics, with the goal of broadening access to clinical research as a care option worldwide.

Tomasz Dąbrowski, CEO of Humaneva, Inc., advises, “Partnering with Viking is a strategic milestone for us. Viking’s unique blend of hedge fund and private equity expertise, coupled with their long-term, value-building perspective, aligns perfectly with Humaneva’s vision.”

„Cooperation with our new partner may result in prospective new contacts and greater trust in our company from the US market players. This transaction is also proof of the high potential of this area and thus of the long-term prospects of the Group as well as the credibility of our activities and confirms the correctness of the growth trajectory for the segment pursued so far.” – says Grzegorz Dzik, Vice President of the Board of Directors of NEUCA S.A.

“Congratulations to Neuca S.A., Humaneva, Inc., and Viking Global Investors on completing such a significant transaction supporting the development of the Pharmaceutical and Biotechnology sectors. This is a showcase scenario of rapidly developing services that are crucial not only for the economy but also for advancements in scientific and medical fields. This includes the development of new therapies, drugs, and innovative medical solutions that directly enhance the quality of life and extend its duration. Great to see Polish companies going global and proving the attractiveness of their business models to serious investors. We are honored to have been able to assist our clients in this process.” adds Rafał Stroiński (Senior Partner at B2RLaw).

The B2RLaw transactional team was led by Rafał Stroiński (Senior Partner) and consisted of  Magdalena Borychowska (Associate) and Danyila Zubach (Associate), Konrad Czernecki (Associate) and Konrad Zając (Associate).

On this transaction we were accompanied by the transactional team of Pillsbury Winthrop Shaw Pittman LLP led by Stan Lewandowski (Partner) with the support of Laura L. McDaniels (Partner) and Ann Kim (Associate).